PeterCAdamsonMD

Pediatric Hematology & Oncology • Cambridge, MA

Global Head, Oncology Development & Pediatric Innovation, Sanofi

Join to view full profile

Dr. Adamson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Adamson's full profile

Already have an account?

Office
450 Water St
Cambridge, MA 02141
Phone+1 617-685-5841
Is this information wrong?

Education & Training

Clinical Center at the National Institutes of HealthFellowship, Biotechnology , 1990 - 1992
NIH Clinical Ctr1987 - 1990
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1984 - 1987
Weill Cornell MedicineClass of 1984
Wesleyan UniversityBA, Chemistry, 1976 - 1980

Certifications & Licensure

PA State Medical License 1986 - 2024
MD State Medical License 1988 - 2000

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2006-2013
Philadelphia Magazine Castle Connolly, 2006-2008, 2010-2012
Special Recognition Award National Cancer Institute, 2005
Children's Cancer Foundation Research Scholar 1992
Overall excellence in clinical and interpersonal skills 1987
Phi Beta Kappa 1980
Overall excellence in leadership and scholarship The Wesleyan, 1979
Certificate of Appreciation United States Army Medical Research, 1999-2004
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 1996 Jun 01
Completed
Phase 2
Surgery in Treating Children With Neuroblastoma Start of enrollment: 1998 Mar 01
Completed
Phase 3
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Start of enrollment: 1997 Mar 01
Completed
Phase 3
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Start of enrollment: 2000 Apr 01
Completed
Phase 3
Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Start of enrollment: 2000 Oct 01
Completed
Phase 3
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Start of enrollment: 2002 Oct 01
Completed
Phase 3
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Start of enrollment: 2001 Jul 01
Completed
Fluconazole Pharmacokinetics in Infants Start of enrollment: 2005 Nov 01
Completed
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Start of enrollment: 2008 Jan 01
Completed
Phase 2
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 24
Withdrawn
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group Start of enrollment: 2010 Apr 30
Terminated
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial Start of enrollment: 2012 Mar 01
Completed
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation Start of enrollment: 2012 Apr 01
Active, not recruiting
Phase 2
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients Start of enrollment: 2011 Dec 01
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

13 citations
Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from ...
Tamara P Miller, Kelly D Getz, Yimei Li, Biniyam G Demissei, Peter C Adamson, Todd A Alonzo, Evanette Burrows, Lusha Cao, Sharon M Castellino, Marla H Daves, Brian T F...> ;The Lancet. Haematology. 2022 Sep 1
12 citations
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal ...
G. A. Amos Burke, Veronique Minard-Colin, A. Auperin, Sarah Alexander, Marta Pillon, Rafael Delgado, Jozsef Zsiros, Anne Uyttebroeck, Peggy Dartigues, Rodney R. Miles,...> ;Journal of Clinical Oncology. 2021 Sep 27
20 citations
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Jack Su, Lindsay Kilburn, David B Mansur, Mark Krailo, Allen Buxton, Adesina Adekunle, Amar Gajjar, Peter C Adamson, Brenda J. Weigel, Elizabeth Fox, Susan M. Blaney, ...> ;Neuro-Oncology. 2021 Aug 4
Foreword to special issue on radiation oncology.
Peter C. Adamson, Giorgio Perilongo> ;Pediatric Blood & Cancer. 2021 Apr 5
49 citations
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Jennifer Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Bre...> ;Clinical Cancer Research. 2021 Feb 10
17 citations
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with p...
Andrew D.J. Pearson, Kimberly Stegmaier, Franck Bourdeaut, Gregory H. Reaman, Delphine Heenen, Michael L. Meyers, Scott A. Armstrong, Patrick A. Brown, Daniel D. De Ca...> ;European Journal of Cancer. 2020 Nov 1
25 citations
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medi...
Andrew D.J. Pearson, C. Michel Zwaan, E. Anders Kolb, Dominik Karres, Julie Guillot, Su Young Kim, Lynley V. Marshall, Sarah K. Tasian, Malcolm A. Smith, Todd M. Coope...> ;European Journal of Cancer. 2020 Sep 1
21 citations
Pediatric cancer research: Surviving COVID-19.
Jeffery J. Auletta, Peter C. Adamson, Jonathan E. Agin, Pamela Kearns, Scott Kennedy, Mark W. Kieran, Donna Ludwinski, Leona Knox, Kristi McKay, Pia Rhiner, Carol J. T...> ;Pediatric Blood & Cancer. 2020 Jun 18
108 citations
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
Veronique Minard-Colin, Anne Auperin, Marta Pillon, G. A. Amos Burke, Donald A. Barkauskas, Keith Wheatley, Rafael Delgado, Sarah Alexander, Anne Uyttebroeck, Catherin...> ;The New England Journal of Medicine. 2020 Jun 3
22 citations
Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of Cancer.
Anne H. Blaes, Peter C. Adamson, Lewis E. Foxhall> ;JCO Oncology Practice. 2020 Apr 8
1 citations
Early Phase Pediatric Cancer Trials: Progress Highlights Challenges.
Peter C. Adamson> ;The Oncologist. 2020 Jun 1
39 citations
Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.
Tamara P. Miller, Brian T. Fisher, Kelly D. Getz, Leah Sack, Hanieh Razzaghi, Alix E. Seif, Rochelle Bagatell, Peter C. Adamson, Richard Aplenc> ;Pediatric Blood & Cancer. 2019 Jul 1
1 citations
Emergent Radiation for Leukemic Optic Nerve Infiltration in a Child Receiving Intrathecal Methotrexate.
Michael J. LaRiviere, Robert A. Avery, J. Gregory Dolan, Peter C. Adamson, Deborah M. Zarnow, Yunhe Xie, Stephen Avery, G. Kurtz, Christine E. Hill-Kayser, Robert A. L...> ;Practical Radiation Oncology. 2019 Jul 1
44 citations
Insights into pediatric rhabdomyosarcoma research: Challenges and goals
Marielle E. Yohe, Christine M. Heske, Elizabeth Stewart, Peter C. Adamson, Nabil Ahmed, Cristina R. Antonescu, Eleanor Y. Chen, Natalie Collins, Alan R. Ehrlich, Rene ...> ;Pediatric Blood & Cancer. 2019 Jun 21
4 citations
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
Peter C. Adamson, Gareth J. Veal, Richard B. Womer, Holly J. Meany, M. Brooke Bernhardt, A. Lindsay Frazier, Frank M. Balis> ;Pediatric Blood & Cancer. 2019 Jun 1
34 citations
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Andrew D.J. Pearson, Nicole Scobie, Koenraad Norga, Franca Ligas, Davy Chiodin, Amos Burke, Veronique Minard-Colin, Peter C. Adamson, Lynley V. Marshall, Arun Balakuma...> ;European Journal of Cancer. 2019 Mar 1
10 citations
The Children's Oncology Group: Organizational Structure, Membership, and Institutional Characteristics.
Janice S. Withycombe, Todd A. Alonzo, Michele A Wilkins-Sanchez, Maxine Hetherington, Peter C. Adamson, Wendy Landier> ;Journal of Pediatric Oncology Nursing. 2019 Jan 1
6 citations
Dose Intensification Improves the Outcome of Ewing Sarcoma.
Richard Gorlick, Katherine A. Janeway, Peter C. Adamson> ;Journal of Clinical Oncology. 2018 Sep 12
11 citations
New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review.
Sonya Das, Raphaël Rousseau, Peter C. Adamson, Andrew W. Lo> ;JAMA Oncology. 2018 Sep 1
51 citations
Antisense Therapy for a Common Corneal Dystrophy Ameliorates TCF4 Repeat Expansion-Mediated Toxicity
Christina Zarouchlioti, Beatriz Sanchez-Pintado, Nathaniel J. Hafford Tear, Pontus Klein, Petra Liskova, Kalyan Dulla, Ma'ayan Semo, Anthony A. Vugler, Kirithika Muthu...> ;American Journal of Human Genetics. 2018 Apr 5
41 citations
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginas...
Rachel E. Rau, ZoAnn E. Dreyer, Mi Rim Choi, Wei Liang, Roman Skowronski, Krishna P. Allamneni, Meenakshi Devidas, Elizabeth A. Raetz, Peter C. Adamson, Susan M. Blane...> ;Pediatric Blood & Cancer. 2018 Mar 1
238 citations
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Yael P. Mosse, Stephan D. Voss, Megan S. Lim, Delphine Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel> ;Journal of Clinical Oncology. 2017 Aug 8
27 citations
Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases
Frederick S. Kaplan, Jeffrey R. Andolina, Peter C. Adamson, David T. Teachey, Jerry Z. Finklestein, David H. Ebb, Benjamin Whitehead, Benjamin Jacobs, David M. Siegel,...> ;Bone. 2017 Jul 20
4 citations
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Tamara P. Miller, Yimei Li, Marko Kavcic, Kelly D. Getz, Yuan-Shun V Huang, Lillian Sung, Todd A. Alonzo, Robert B. Gerbing, Marla Daves, Terzah M. Horton, Michael A. ...> ;Haematologica. 2017 Sep 1
17 citations
Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force
Frank M. Balis, Richard B. Womer, Stacey L. Berg, Naomi J. Winick, Peter C. Adamson, Elizabeth Fox> ;Pediatric Blood & Cancer. 2017 May 16
Join now to see all

Journal Articles

Acute pancreatitis following ifosfamide.
Izraeli S, Adamson PC, Blaney SM, Balis FM, Cancer; 74(5):1627-1628
A phase I trial of amifostine (WR-2721) and melphalan in pediatric patients with advanced neoplastic disease.
Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG, Cancer Res; 55:4069-4072
Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey.
Adamson PC, Murphy RF, Godwin KA, Ulm EH, Balis FM, Cancer Res; 55(3):482-485
Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule.
Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM, J Clin Oncol; 13(5):1238-1241
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma.
Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R, J Clin Oncol;13(8):1966-1974
Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC, Cancer; 76(3):521-526
Pharmacology and drug resistance in childhood lymphoblastic leukemia.
Adamson PC, Poplack DG, Balis FM, Hematol Oncol Clin North Am; 4(5):871-894
The child with recurrent solid tumor.
Adamson PC, Horowitz ME, Poplack DG, Pediatr Clin North Am; 38(2):489-504
Reinvestigation of the matrix IR spectrum of peroxyacetylnitrate (PAN).
Adamson P, Gunthard HH, Spectrochim Acta
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RL, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM, Cancer; 78(3):527-531
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study
Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM., J Clin Oncol
Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2.
O'Marcaigh AS, Johnson CM, Smithson WA, Patterson MC, Widemann BC, Adamson PC, McManus MJ, Mayo Clin Proc; 71(2):161-165
Pharmacokinetic variability and apparent drug resistance.
Adamson PC, Poplack DG, Int J Pediatr Hematol Oncol; 4(6):525-530
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule with interferon-alfa-2a in pediatric patients with refracto...
Adamson PC, Reaman G, Finkelstein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM, J Clin Oncol;15(11):3330-3337
Pediatric phase I trial of Docetaxel administered as a 1-hour infusion: A collaborative Pediatric Branch, National Cancer Institute and Children’s Cancer Group trial.
Blaney SM, Seibel N, O’Brien M, Reaman G, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM, J Clin Oncol; 15(4):1538-1543
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT, Adamson PC, Gupta M, Sandstrom K, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R, Clin. Cancer Res; 4:635-642
A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Kitchen BJ, Balis FM, Poplack DG, O'Brien M, Craig CE, Adamson PC, Clin Cancer Res; 3(5):713-7
Carboxypeptidase-G2, thymidine and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC, Balis FM, Murphy RF, Sorenson MJ, Montello MJ, O’Brien M, Adamson PC, J Clin Oncol; 15(5):2125-2134
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM, J Clin Oncol;16(1):181-186
Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: A Collaborative Pediatric Branch, National Cancer I...
Blaney S, Needle M, Gillespie A, Sato J, Reaman G, Berg S, Adamson P, Krailo M, Bleyer W, Poplack D, Balis F, Clin Cancer Res;4:357-360
Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine.
Kitchen BJ, Moser A, Lowe E, Balis FM, Brigitte Widemann, Anderson L, Strong J, Blaney SM, Berg SL, O’Brien M, Adamson PC, J Pharmacol Exp Ther; 291:870–874
Intraventricular concentration times time (CxT) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma.
Moser AM, Adamson PC, Gillespie AJ, Poplack DG, Balis FM, Cancer; 85(2):511-516
Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader.
Widemann BC, Balis FM, Adamson PC, Clin Chem; 45(2):223-8
The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
Widemann BC, Balis FM, Godwin KS, McCully C, Adamson PC, Cancer Chemother Pharmacol; 44(6):439-43
Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia.
Longui CA, Vottero A, Adamson PC, Cole DE, Kino T, Monte O, Chrousos GP, Horm Metab Res; 32(10):401-6
Join now to see all

Books/Book Chapters

Drug resistance in leukemia and lymphoma: The clinical value of laboratory studies.
Chapter: Pharmacologic factors involved in the response to chemotherapy: apparent versus intrinsic drug resistance
Page 33 - 39Adamson P, Poplack DEditors: Kaspers GJL, Pieters R, Twentyman PR, Wiesenthal LM, Veerman AJP.Harwood Academic Publishers, Chur, Switzerland
Cancer in the Nervous System.
Chapter: Pharmacologic approaches to treatment of meningeal metastases
Page 291 - 301Adamson PC, Poplack DGEditors: Levin VA.Churchill Livingstone, New York
Making better drugs for children with cancer.
National Cancer Policy Board (U.S.). Committee on Shortening the Time Line for New Cancer Treatments., Adamson PC, Weiner SL, Simone JV, Gelband HNational Academies Press, Washington, D.C
Pediatric secrets.
Chapter: Oncology
Page 514 - 543Aplenc R, Skolnik J, Adamson PCEditors: Polin RA, Ditmar MF.Mosby, PhiladelphiaEdition 4th,
Cancer in children.
Chapter: Future trends in cancer chemotherapy
Page 56 - 67Fox E, Adamson PCEditors: Voute PA, Barrett A, Stevens MCG, Caron HN.Oxford University Press, OxfordEdition 5th,
Principles and practice of pediatric oncology.
Chapter: General principles of chemotherapy
Page 290 - 365Adamson PC, Balis FM, Berg S, Blaney SMEditors: Pizzo PA, Poplack DG.Lippincott Williams & Wilkins, PhiladelphiaEdition 5th,
Treatment of Acute Leukemias: New Directions for Clinical Research.
Chapter: Antipurines in Childhood Acute Lymphoblastic Leukemia
Page 297 - 308Gaynon P, Adamson PEditors: Pui C-H.Humana Press, Totowa
Treatment of Acute Leukemias: New Directions for Clinical Research.
Chapter: Antipurines in Childhood Acute Lymphoblastic Leukemia
Page 395 - 403Gaynon P, Adamson PHumana Press, Totowa
Conn's Current Therapy 2000.
Chapter: Acute leukemia in children
Page 421 - 425Adamson PCEditors: Rakel RE.WB Saunders, PhiladelphiaEdition 52nd,
Oncology.
Chapter: Pediatric solid tumors
Page 385 - 413Adamson PC, Widemann BCEditors: Spence RAJ, Johnston PG.Oxford University Press, Oxford
Pediatric secrets.
Chapter: Oncology
Page 575 - 611Langmuir P, Aplenc R, Adamson PCEditors: Polin RA, Ditmar. MF.Hanley & Belfus, PhiladelphiaEdition Thir,
Handbook of Anti-Cancer Drug Development.
Chapter: Phase I Trial Design: Considerations in the Pediatric Population
Page 297 - 308Fox E, Adamson PCEditors: Budman D, Calvert H, Rowsinki E.Lippincott Williams & Wilkins
Cancer in Children and Adolescents.
Chapter: Fundamentals of Cancer Chemotherapy
Page 95 - 112Widemann BC, Adamson PCEditors: Carroll WL, Finlay JL.Jones and Bartlett, Boston
Join now to see all

Abstracts/Posters

Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.
Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM, ASCO Meeting Abstracts
Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).
Lipsitz EG, Nguyen V, Zhao H, Ecsedy J, Maris JM, Adamson PC, Mosse YP, ASCO Meeting Abstracts; 28(15_suppl):10593. PMID
A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Cons...
Mosse YP, Lipsitz EG, Maris JM, Weigel B, Adamson PC, Ingle M, Ahern CH, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9529
A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.
Park JR, Hawkins DS, Ingle M, Borinstein SC, Glade Bender JL, Yamashiro D, Baruchel S, Chen AP, Adamson PC, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9530. PMID
Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.
Warwick AB, Malempati S, Krailo MD, Melemed AS, Adamson PC, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9535. PMID
Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial.
Glade Bender JL, Lee A, Adamson PC, Ingle AM, Ahern CH, Wu B, Baruchel S, Harris PJ, Ames MM, Weigel B, Blaney S, Children's Oncology Group, ASCO Meeting Abstracts; 29(15_suppl):9501. PMID
Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the...
Aplenc R, Fisher BT, Sung L, Keren R, Alonzo TA, Hall M, Huang Y-SV, Li Y, Luan X, Gerbing RB, Bertoch D, Seif AE, Adamson PC, Gamis AS, ASH Annual Meeting Abstracts:118(21):2617. PMID
Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncol...
Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Whitlock JA, Adamson PC, Hunger SP, Carroll WL, ASH Annual Meeting Abstracts; 118(21):573. PMID
Treatment of relapse in childhood acute lymphoblastic leukemia. Acute lymphoblastic leukemia.
Adamson PC, The cutting edge
Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group Phase I Consortium.
Aplenc R, Strauss LC, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Blaney SM, Adamson PC, ASCO Meeting Abstracts;26(15_suppl):3591
A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: A Children's Oncology Group Phase I Consortium study.
DuBois SG, Shusterman S, Ingle AM, Baruchel S, Stempak D, Sun J, Ivy SP, Glade-Bender J, Blaney SM, Adamson PC, Children's Oncology Group Phase C, ASCO Meeting Abstracts; 26(15_suppl):3561
A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medull...
Fouladi M, Park JR, Sun J, Ingle AM, Ames MM, Stewart CF, Gilbertson R, Zwiebel JA, Adamson PC, Blaney SM., ASCO Meeting Abstracts;26(15_suppl):10012
Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Jacobs S, Fox B, Krailo MD, Hartley G, Navid F, Wexler L, Blaney SM, Frank B, Adamson PC, Widemann BC, ASCO Meeting Abstracts; 26(15_suppl):10026
Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children's Oncology Group phase I consort...
Russell H, Cairo MS, Blaney SM, Adamson PC, Ingle AM, Berg S, ASCO Meeting Abstracts; 26(15_suppl):13532
Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A Children's Oncology Group phase I consortium study.
Souid A, Dubowy RL, Greenwald Triplett D, Ingle AM, Sun J, Blaney SM, Adamson PC, Meeting Abstracts;26(15_suppl):10014
Phase I and pharmacokinetic (PK) study of lenalidomide (LEN) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndrome (MDS): A Children'...
Berg SL, Russell H, Cairo M, Ingle AM, Adamson PC, Blaney SM, ASCO Meeting Abstracts;27(15S):10023
A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Jr, Fox FE, Voss S, Adamson PC, Blaney SM, ASCO Meeting Abstracts
Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children...
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC, ASCO Meeting Abstracts
Join now to see all

Lectures

Early Phase Cancer Drug Development in Children.
Philadelphia, PA, 2007; Boulder, CO, 2008
Development of Targeted Therapy for Children with Cancer.
Ely Brent Visiting Professor The Children’s Hospital, Denver Cancer Center Rounds
New Agents for Children with Cancer.
Pediatric Grand Rounds, Denver, CO
Imaging in Early Phase Childhood Cancer Trials.
ALARA Concept in Pediatric Imaging Annual Meeting, Scottsdale, AZ
Leveraging Opportunities: The Importance of Pediatric Study Design.
American College of Clinical Pharmacology 37th Annual Meeting, Philadelphia, PA
Early Phase Drug Development in Children.
20th Annual EORTC-NCI-AACR Meeting, Geneva, Switzerland
Signal Transduction Inhibitors for Childhood Cancer: The Children's Oncology Group Experience.
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
Clinical and Translational Research in an Era of Molecularly Targeted Therapy.
The Children’s Hospital of Philadelphia, Philadelphia, PA
Cancer Drug Development: 21st Century Science, 20th Century Clinical Trials.
Houston, TX, 2009, 2010
Drug formulations for children with cancer: What’s old is new again.
FDA Oncology Drug Advisory Pediatric Subcommittee, Bethesda, MD
Restructuring the Children’s Oncology Group Clinical Research Enterprise.
Texas Children’s Cancer Center Grand Rounds, Houston, TX
Childhood Cancer Research.
Wilmington, DE, 2010; Washington, DC, 2010
Childhood Cancer.
Cancer Policy Roundtable National Coalition for Cancer Survivorship, Washington, DC
Strategies to Improve Intrathecal Therapy.
American Society Pediatric Hematology Oncology, Montreal, Canada
Targeted Drug Development for Children with Cancer.
Israeli Society Pediatric Hematology Oncology, K Ginossar, Israel
Restructuring the COG Clinical Trials Enterprise.
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
Phase 1 Trials in Children with Cancer.
Accelerating Anticancer Agent Development and Validation FDA-AACR Workshop, Bethesda, MD
Childhood Cancer Research: 21st Century Science, 20th Century Clinical Trials.
Kansas City, MO, 2010; Minneapolis, MN, 2010; Seattle, WA, 2010; Birmingham, AL, 2011, Boston, MA
Teach Your Parents Well: Personalized Rx in Children with Cancer.
Personalized Cancer Therapeutics Fall Symposium, University of Chicago Chicago, IL
Clinical Development of Immunotherapy: A View from the COG.
2nd International Conference on Immunotherapy in Pediatric Oncology, Houston, TX
Clinical Trials Experience With Cardiac Safety.
Cardiac Safety Research Consortium, White Oak Facility, FDA Headquarters Silver Springs, MD
Development of Targeted Agents for Children with Cancer.
Lund, Sweden, 2011; Moscow, Russia, 2011
Teach Your Parents Well: Leads from Childhood Cancer Research.
Karmanos Cancer Institute Grand Rounds, Detroit, MI
Development of Targeted New Agents for Children with Cancer.
Melissa Ann Krinsky Memorial Lecture, Detroit, MI
New Oncology Drug Development for Children and Adolescents in Europe: Where are we after 5 years of the EU Paediatric Medicine Regulation? Where to Go?
Biotherapy Development Association Workshop, London, England
Join now to see all

Press Mentions

Sanofi - Sarclisa (Isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Patients with Relapsed Multiple Myeloma Receiving a Proteasome Inhibitor TherapyMay 18th, 2022
Cancer Is the Leading Cause of “Death from Disease” in Children. Here’s WhyDecember 3rd, 2021
Additional Pediatric Cancer Funding in the Offing?April 1st, 2019
Join now to see all